Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H28N2O5 |
Molecular Weight | 472.5323 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](OC1=C25)[C@@H](CC[C@@]36O)N7C(=O)C8=C(C=CC=C8)C7=O
InChI
InChIKey=DHAITNWJDOSRBU-IBHWKQIPSA-N
InChI=1S/C28H28N2O5/c31-20-8-7-16-13-21-28(34)10-9-19(30-25(32)17-3-1-2-4-18(17)26(30)33)24-27(28,22(16)23(20)35-24)11-12-29(21)14-15-5-6-15/h1-4,7-8,15,19,21,24,31,34H,5-6,9-14H2/t19-,21-,24+,27+,28-/m1/s1
Molecular Formula | C28H28N2O5 |
Molecular Weight | 472.5323 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Naltalimide (TRK-130), a mu opioid receptor partial agonist, is being developed by Toray Industries for the treatment of overactive bladder. A phase IIb trial is underway in Japan. In radioligand-binding assays with cells expressing human µ-opioid receptors (MORs), δ-opioid receptors (DORs), or κ-opioid receptors (KORs), TRK-130 showed high selectivity for MORs (Ki for MORs, DORs, and KORs = 0.268, 121, and 8.97 nM, respectively). TRK-130 is a potent and selective human MOR partial agonist without undesirable opioid adverse effects such as constipation and enhances the storage function by suppressing the afferent limb of the micturition reflex pathway.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28093646
Rats: Naltalimide (0.001-0.01 mg/kg, iv) dose-dependently inhibited RBCs, which was dose-dependently antagonized by naloxone; however, the antagonism susceptibility was different from morphine (1 mg/kg, iv). The minimum effective dose (0.003 mg/kg) of Naltalimide remained similar in spinal cord-transected animals. Naltalimide (0.0025 mg/kg, iv) increased bladder capacity without changing the voiding efficiency, maximum flow rate, and intravesical pressure at the maximum flow rate, whereas oxybutynin (1 mg/kg, iv) increased the bladder capacity but affected the other parameters. Naltalimide (0.005 mg/kg, iv) did not produce significant changes on the bladder contractions induced by peripheral stimulation of the pelvic nerve, while oxybutynin (1 mg/kg, iv) significantly suppressed the bladder contractions.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24928951
In radioligand-binding assays with cells expressing human µ-opioid receptors (MORs), δ-opioid receptors (DORs), or κ-opioid receptors (KORs), TRK-130 showed high selectivity for MORs (Ki for MORs, DORs, and KORs = 0.268, 121, and 8.97 nM, respectively). In a functional assay (cAMP accumulation) with cells expressing each human opioid receptor subtype, TRK-130 showed potent but partial agonistic activity for MORs [EC50 (Emax) for MORs, DORs, and KORs = 2.39 nM (66.1%), 26.1 nM (71.0%), and 9.51 nM (62.6%), respectively].
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:32:22 GMT 2023
by
admin
on
Sat Dec 16 01:32:22 GMT 2023
|
Record UNII |
PUO0LMS4NX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PUO0LMS4NX
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
DTXSID10166868
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545408
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
160359-68-2
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
Naltalimide
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
C174856
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
300000034307
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
9548
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY | |||
|
16066809
Created by
admin on Sat Dec 16 01:32:22 GMT 2023 , Edited by admin on Sat Dec 16 01:32:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|